1-11 of 11
Alan J. Korman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1351: Preclinical characterization of BMS-986288, a novel non-fucosylated (NF) anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) Probody® therapeutic

Free
Amy Jhatakia, Mohammed Nasser, Anandaroop Mukhopadhyay, Kyeongah Kang, Courtni Newsome, Neha Gupta, Remie Gail Z. Mandawe, Felix Findeisen, Jack A. Lohre, Leslie Leung, Yun Wei, Joshua Dobroff, Karen Price, John Engelhardt, Mark Selby, Alan J. Korman, Nicholas Wilson
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1351.
https://doi.org/10.1158/1538-7445.AM2024-1351
Published: 22 March 2024
View articletitled, Abstract 1351: Preclinical characterization of BMS-986288, a novel non-fucosylated (NF) anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) Probody® therapeutic
Journal Articles

Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models

Available to Purchase
Joseph R. Campbell, Bryan R. McDonald, Paul B. Mesko, Nathan O. Siemers, Priti B. Singh, Mark Selby, Tim W. Sproul, Alan J. Korman, Logan M. Vlach, Jeff Houser, Sharmila Sambanthamoorthy, Kai Lu, Sandra V. Hatcher, Jack Lohre, Renu Jain, Ruth Y. Lan
Journal: Cancer Research
Cancer Res (2021) 81 (11): 2983–2994.
https://doi.org/10.1158/0008-5472.CAN-20-3585
Published: 01 June 2021
View articletitled, Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models
Open the PDF for Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models in another window
Includes: Supplementary data
Journal Articles

Abstract 4085: DDR2 inhibition enhances response to anti-PD-1 immunotherapy

Free
Megan M. Tu, Francis Y. Lee, Robert T. Jones, Abigail K. Kimball, Elizabeth Saravia, Robert F. Graziano, Brianne Coleman, Krista Menard, Jun Yan, Erin Michaud, Han Chang, Hany A. Abdel-Hafiz, Andrii I. Rozhok, Jason E. Duex, Neeraj Agarwal, Ana Chauca-Diaz, Linda K. Johnson, Terry L. Ng, John C. Cambier, Eric T. Clambey, James C. Costello, Alan J. Korman, Dan Theodorescu
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4085.
https://doi.org/10.1158/1538-7445.AM2019-4085
Published: 01 July 2019
View articletitled, Abstract 4085: DDR2 inhibition enhances response to anti-PD-1 immunotherapy
Journal Articles

Abstract 1548: Acidic pH selective binding of VISTA to PSGL-1 and anti-tumor activity of combined VISTA and PD-1 blockade

Free
Robert J. Johnston, Linhui Julie Su, Jason Pinckney, David Critton, Arathi Krishnakumar, Martin Corbett, Andrew Rankin, Rose A. DiBella, Lynne Campbell, Xiaodi Deng, Haibin Chen, Alexander Kozhich, Jim Holloway, Zheng Yang, Ginger Rakestraw, Michael Quigley, Alan J. Korman
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1548.
https://doi.org/10.1158/1538-7445.AM2019-1548
Published: 01 July 2019
View articletitled, Abstract 1548: Acidic pH selective binding of VISTA to PSGL-1 and anti-tumor activity of combined VISTA and PD-1 blockade
Journal Articles

Abstract SY09-01: Next-generation anti-CTLA-4 antibodies

Free
Alan J. Korman, John Engelhardt, John Loffredo, Jose Valle, Rahima Akter, Raja Vuyyuru, Natalie Bezman, Paula So, Robert Graziano, Kimberly Tipton, James West, Bryan Irving, Mark Selby
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): SY09-01.
https://doi.org/10.1158/1538-7445.AM2017-SY09-01
Published: 01 July 2017
View articletitled, Abstract SY09-01: Next-generation anti-CTLA-4 antibodies
Journal Articles

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor

Free
Shin Foong Ngiow, Arabella Young, Stephen J. Blake, Geoffrey R. Hill, Hideo Yagita, Michele W. L. Teng, Alan J. Korman, Mark J. Smyth
Journal: Cancer Research
Cancer Res (2016) 76 (21): 6266–6277.
https://doi.org/10.1158/0008-5472.CAN-16-2141
Published: 31 October 2016
View articletitled, Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor
Open the PDF for Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor in another window
Includes: Supplementary data
Journal Articles

Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab

Free
Yoshinobu Koguchi, Helena M. Hoen, Shelly A. Bambina, Michael D. Rynning, Richard K. Fuerstenberg, Brendan D. Curti, Walter J. Urba, Christina Milburn, Frances Rena Bahjat, Alan J. Korman, Keith S. Bahjat
Journal: Cancer Research
Series: Author Choice
Cancer Res (2015) 75 (23): 5084–5092.
https://doi.org/10.1158/0008-5472.CAN-15-2303
Published: 30 November 2015
View articletitled, Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Open the PDF for Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab in another window
Includes: Supplementary data
Journal Articles

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice

Free
Miguel F. Sanmamed, Inmaculada Rodriguez, Kurt A. Schalper, Carmen Oñate, Arantza Azpilikueta, Maria E. Rodriguez-Ruiz, Aizea Morales-Kastresana, Sara Labiano, Jose L. Pérez-Gracia, Salvador Martín-Algarra, Carlos Alfaro, Guillermo Mazzolini, Francesca Sarno, Manuel Hidalgo, Alan J. Korman, Maria Jure-Kunkel, Ignacio Melero
Journal: Cancer Research
Cancer Res (2015) 75 (17): 3466–3478.
https://doi.org/10.1158/0008-5472.CAN-14-3510
Published: 31 August 2015
View articletitled, Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice
Open the PDF for Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice in another window
Includes: Supplementary data
Journal Articles

Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice

Free
Miguel F. Sanmamed, Inmaculada Rodriguez, Carmen Oñate, Arantza Azpilikueta, Maria E. Rodriguez-Ruiz, Aizea Morales-Kastresana, Sara Labiano, Jose L. Perez-Gracia, Salvador Martín-Algarra, Carlos Alfaro, Kurt A. Schalper, Guillermo Mazzolini, Francesca Sarno, Manuel Hidalgo, Alan J. Korman, Maria Jure-Kunkel, Ignacio Melero
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 261.
https://doi.org/10.1158/1538-7445.AM2015-261
Published: 01 August 2015
View articletitled, Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice
Journal Articles

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Free
Seng-Ryong Woo, Meghan E. Turnis, Monica V. Goldberg, Jaishree Bankoti, Mark Selby, Christopher J. Nirschl, Matthew L. Bettini, David M. Gravano, Peter Vogel, Chih Long Liu, Stephanie Tangsombatvisit, Joseph F. Grosso, George Netto, Matthew P. Smeltzer, Alcides Chaux, Paul J. Utz, Creg J. Workman, Drew M. Pardoll, Alan J. Korman, Charles G. Drake, Dario A.A. Vignali
Journal: Cancer Research
Cancer Res (2012) 72 (4): 917–927.
https://doi.org/10.1158/0008-5472.CAN-11-1620
Published: 14 February 2012
View articletitled, Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Open the PDF for Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape in another window
Includes: Supplementary data
Journal Articles

Abstract LB-251: The checkpoint molecules LAG-3 and PD-1 synergize to maintain tolerance to tumors

Free
Monica V. Goldberg, Seng-Ryong Woo, Jaishree Bankoti, Mark Selby, Christopher J. Nirschl, Matthew L. Bettini, Peter Vogel, Joseph F. Grosso, George Netto, Alcides Chaux, Matthew Smeltzer, Creg J. Workman, Drew M. Pardoll, Alan J. Korman, Dario AA Vignali, Charles G. Drake
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): LB-251.
https://doi.org/10.1158/1538-7445.AM2011-LB-251
Published: 15 April 2011
View articletitled, Abstract LB-251: The checkpoint molecules LAG-3 and PD-1 synergize to maintain tolerance to tumors